The Foundation/ Friends Evidence Accelerator



for the Food and Drug Administration



https://evidenceaccelerator.org/







The COVID-19 Evidence Accelerator is an initiative launched by the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research (Friends), to provide a unique venue for major data organizations, government and academic researchers, and health systems to gather and design quick-turn-around queries and share their results.

The Accelerator brings together the country's leading experts in health data aggregation and analytics in a unified effort to share insights, compare results, and answer key questions about COVID-19 treatment and response as quickly as possible.

Urgency and Action: Since the beginning of the pandemic, data scientists around the country have been engaged in an intense effort to capture real-world data and rapidly deploy data analytics to help answer key questions related to the management of COVID-19 patients. These individual efforts are developing into valuable insights, by banding together we are collectively accelerating and maximizing the utility of this information. To do this effectively, a core set of common data elements have been developed that allow any willing data collection effort to embed these data elements into their on-going work in a uniform way to allow for rapid aggregation and analysis.

Combining efforts will make the findings more robust and accelerate answers.

Participants in the COVID-19 Evidence Accelerator helped develop an initial set of Key Questions and Core Data Elements that could be used in research using various real-world data sets


Click here for Summary of Key Questions and Core Data Elements

Two Interactive Work Streams:

1) Accelerator Parallel Analyses: Developing key research questions that multiple organizations and teams can address simultaneously.

Initial activities of this work stream include (1) rapidly revising a list of core data elements; (2) identifying those critical to answering the primary question; and (3) establishing uniform collection parameters. It will be necessary to work collaboratively to determine how data elements are being extracted and how they are being defined in order to operationalize a platform that can not only answer questions now, but also inform how research activities could be conducted in

Real-World Data for COVID-19




Our Responsibility

The Evidence Accelerator provides a "safe space" for key players across the ecosystem to lead, scrutinize and "get this right"

RWD Priorities


- Data selection
- Protocol design
- Transparency
- Data provenance
- Data quality
- Analytical integrity
- Peer review
- Press interactions





COVID-19 EVIDENCE ACCELERATOR PRINCIPLES

Together, we will **create** and **lead**.



- **RESPECT** for patient privacy and the patient voice is paramount.
- **EARN TRUST** show processes, analytic approaches, and comparisons. Be open to input. Challenge with productive intent.
- ACT FAST AND DO GOOD WORK—
 act with a sense of urgency, but not
 at the expense of quality or credibility.
- TRANSPARENCY ruthless transparency.
- **EMBRACE AND EXPLORE** —convergence and discordance to facilitate understanding and generate knowledge.

- **LEARN** continually integrate best practices from **sharing** process, limitations, pitfalls, and successes.
- **EXERCISE PATIENCE** state when a question can't be answered right away and institute action to answer it.
- ACCESSIBILITY AND TRACEABILITY document data generation, processing, curation, and analytics.
- DISSEMINATE WORK to show what good looks like. Teach, Don't Preach.



